![]() ![]() SIMPONI Aria is the only fully human anti-TNF-alpha infusible therapy. Food and Drug Administration (FDA) approval of SIMPONI ARIA for the treatment of adults with moderately to severely active RA in combination with methotrexate. These data were presented during an oral presentation at the 2013 Annual Meeting of the American College of Rheumatology (ACR). ![]() Treatment with SIMPONI ARIA plus methotrexate also led to improvements in disease activity with nearly 60 percent of patients achieving at least a 20 percent improvement in the American College of Rheumatology (ACR 20) score at week 14, the study’s primary endpoint, and 68 percent achieving that response at week 100. The continued inhibition of structural damage progression was seen in patients randomized to SIMPONI ARIA through weeks 52 and 100, and inhibition of structural damage progression was observed in patients receiving placebo who crossed over to SIMPONI ARIA at weeks 16 or 24. ![]() Analysis of study patients’ X-rays showed significant inhibition of the progression of structural damage at week 24 in patients receiving SIMPONI ARIA plus methotrexate compared with patients receiving placebo plus methotrexate. SAN DIEGO, Octo– New two-year results of a Phase 3 study sponsored by Janssen Research & Development, LLC (Janssen) showed that SIMPONI ® ARIA™ (golimumab) for infusion in combination with methotrexate inhibited radiographic progression in patients with moderately to severely active rheumatoid arthritis (RA) at week 24, and continued to inhibit radiographic progression through weeks 52 and 100. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |